• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.诱导治疗后的病理完全缓解——手术在IIIA/B期局部晚期非小细胞肺癌中的作用
J Thorac Dis. 2018 May;10(5):2795-2803. doi: 10.21037/jtd.2018.05.68.
2
Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.局部晚期非小细胞肺癌根治性放化疗后局部复发行挽救性手术后的长期生存情况
Thorac Cardiovasc Surg. 2018 Mar;66(2):135-141. doi: 10.1055/s-0037-1606597. Epub 2017 Oct 9.
3
Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer.诱导放化疗后手术治疗局部晚期非小细胞肺癌患者病理完全缓解的长期结果。
Eur J Cardiothorac Surg. 2013 Mar;43(3):e71-81. doi: 10.1093/ejcts/ezs622. Epub 2013 Jan 4.
4
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).诱导化疗三联顺铂/紫杉醇,随后同步放化疗顺铂/依托泊苷/45 Gy(1.5 Gy bid)加手术治疗局部晚期非小细胞肺癌(NSCLC)的 10 年长期生存(LTS):一项多中心 II 期试验(CISTAXOL)。
Lung Cancer. 2013 Oct;82(1):83-9. doi: 10.1016/j.lungcan.2013.06.007. Epub 2013 Aug 16.
5
Major Pathologic Response after Induction Therapy Has a Long-Term Impact on Survival and Tumor Recurrence in Stage IIIA/B Locally Advanced NSCLC.诱导治疗后的主要病理反应对ⅢA/B期局部晚期非小细胞肺癌的生存和肿瘤复发具有长期影响。
Thorac Cardiovasc Surg. 2020 Oct;68(7):639-645. doi: 10.1055/s-0039-1679884. Epub 2019 Feb 26.
6
Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.ⅢA 期(N2-肿块型)和ⅢB 期非小细胞肺癌患者的三联疗法治疗结果。
Clin Lung Cancer. 2009 Sep;10(5):353-9. doi: 10.3816/CLC.2009.n.048.
7
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.非小细胞肺癌根治性放疗(>59 Gy)及同步化疗后的肺切除术
Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085.
8
[Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results].[新辅助放化疗后行根治性切除术治疗ⅢA/ⅢB期晚期非小细胞肺癌患者:预后因素及结果]
Zentralbl Chir. 2016 Jun;141(3):323-9. doi: 10.1055/s-0042-101558. Epub 2016 Apr 1.
9
[Treatment outcome of locally advanced stage IIIA/B lung cancer].[局部晚期IIIA/B期肺癌的治疗结果]
Medicina (Kaunas). 2009;45(6):452-9.
10
Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer.局部晚期IIIA/B期非小细胞肺癌中使用和不使用重组人粒细胞集落刺激因子支持的诱导化疗。
Semin Oncol. 1994 Jun;21(3 Suppl 4):20-7.

引用本文的文献

1
Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions.可手术非小细胞肺癌的全身治疗:文献综述与未来方向探讨
J Clin Med. 2025 Jun 11;14(12):4127. doi: 10.3390/jcm14124127.
2
S-1/irinotecan/oxaliplatin chemotherapy achieved a pathological complete remission in advanced pancreatic carcinoma.S-1/伊立替康/奥沙利铂化疗使晚期胰腺癌实现了病理完全缓解。
Clin J Gastroenterol. 2025 Feb;18(1):220-223. doi: 10.1007/s12328-024-02055-1. Epub 2024 Nov 6.
3
Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer.新辅助和围手术期免疫疗法在可切除非小细胞肺癌中不断演变作用的证据。
Explor Target Antitumor Ther. 2024;5(6):1247-1260. doi: 10.37349/etat.2024.00273. Epub 2024 Sep 29.
4
Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection.接受新辅助治疗和肺切除的非小细胞肺癌患者肿瘤退缩和生存的围手术期预测因素
Cancers (Basel). 2024 Aug 20;16(16):2885. doi: 10.3390/cancers16162885.
5
The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges.基于PET/CT影像组学的人工智能在非小细胞肺癌中的作用:疾病管理、机遇与挑战。
Front Oncol. 2023 Mar 7;13:1133164. doi: 10.3389/fonc.2023.1133164. eCollection 2023.
6
Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer.氟脱氧葡萄糖正电子发射断层扫描在预测局部晚期非小细胞肺癌新辅助放化疗后的病理反应和预后中的作用。
Interact Cardiovasc Thorac Surg. 2022 Jul 9;35(2). doi: 10.1093/icvts/ivac113.
7
Predictive Value of F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.利用机器学习的F-FDG PET/CT对Ⅲ期非小细胞肺癌患者新辅助同步放化疗病理反应的预测价值
Cancers (Basel). 2022 Apr 14;14(8):1987. doi: 10.3390/cancers14081987.
8
Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.早期原发性肺腺癌对纳武单抗单药治疗的长期完全缓解
Clin Oncol Case Rep. 2021 Jan;4(1). Epub 2021 Jan 15.
9
Surgery Plus Chemotherapy Versus Surgery Alone for Limited-Stage Small-Cell Lung Cancer: A Population-Based Survival Outcome Analysis.手术联合化疗与单纯手术治疗局限期小细胞肺癌的基于人群的生存结果分析
Front Oncol. 2021 May 17;11:676598. doi: 10.3389/fonc.2021.676598. eCollection 2021.
10
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer].[非小细胞肺癌患者围手术期免疫治疗所致不良事件的临床建议]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):141-160. doi: 10.3779/j.issn.1009-3419.2021.101.06.

本文引用的文献

1
FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)参数预测接受新辅助放化疗和手术的 III 期非小细胞肺癌患者的病理反应和淋巴结清除情况。
Pract Radiat Oncol. 2017 Nov-Dec;7(6):e531-e541. doi: 10.1016/j.prro.2017.04.013. Epub 2017 Apr 19.
2
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).新辅助化疗后乳腺癌的残余癌负担、美国癌症联合委员会分期及病理完全缓解的比较:I-SPY 1试验(CALGB 150007/150012;ACRIN 6657)的结果
Breast Cancer Res Treat. 2017 Aug;165(1):181-191. doi: 10.1007/s10549-017-4303-8. Epub 2017 Jun 2.
3
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.对于局部晚期食管癌患者,与顺铂/紫杉醇联合治疗相比,新辅助放化疗联合顺铂/5-氟尿嘧啶可提高病理完全缓解率并改善生存率。
Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox015.
4
Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.III期非小细胞肺癌(NSCLC)多模式治疗中确定性放化疗与手术的比较——随机证据的累积荟萃分析
Oncotarget. 2017 Jun 20;8(25):41670-41678. doi: 10.18632/oncotarget.16471.
5
The Impact of Pathologic Complete Response in Patients with Neoadjuvantly Treated Locally Advanced Rectal Cancer-a Large Single-Center Experience.新辅助治疗的局部晚期直肠癌患者中病理完全缓解的影响——一项大型单中心经验
J Gastrointest Surg. 2017 Jul;21(7):1153-1158. doi: 10.1007/s11605-017-3408-z. Epub 2017 Apr 6.
6
The Role of F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors.F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描在预测胸腺上皮肿瘤诱导治疗后病理反应中的作用
World J Surg. 2017 Jul;41(7):1828-1833. doi: 10.1007/s00268-017-3938-2.
7
Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.可切除的局部晚期非小细胞肺癌放化疗反应的放射学与病理学相关性
Lung Cancer. 2016 Dec;102:1-8. doi: 10.1016/j.lungcan.2016.10.002. Epub 2016 Oct 14.
8
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.氟[18F]-脱氧葡萄糖正电子发射断层扫描标准化摄取值下降是新辅助化疗后多模式治疗长期预后的预测分类器:可切除 IIIA/B 期非小细胞肺癌的随机试验的二次分析。
J Clin Oncol. 2016 Jul 20;34(21):2526-33. doi: 10.1200/JCO.2015.65.5167. Epub 2016 May 31.
9
Radiomic phenotype features predict pathological response in non-small cell lung cancer.影像组学表型特征可预测非小细胞肺癌的病理反应。
Radiother Oncol. 2016 Jun;119(3):480-6. doi: 10.1016/j.radonc.2016.04.004. Epub 2016 Apr 13.
10
The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?ⅢA-N2期非小细胞肺癌的最佳局部治疗:问题终于解决了吗?
J Thorac Oncol. 2016 Mar;11(3):284-6. doi: 10.1016/j.jtho.2016.01.003.

诱导治疗后的病理完全缓解——手术在IIIA/B期局部晚期非小细胞肺癌中的作用

Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.

作者信息

Schreiner Waldemar, Gavrychenkova Sofiya, Dudek Wojciech, Rieker Ralf Joachim, Lettmaier Sebastian, Fietkau Rainer, Sirbu Horia

机构信息

Division of Thoracic Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.

出版信息

J Thorac Dis. 2018 May;10(5):2795-2803. doi: 10.21037/jtd.2018.05.68.

DOI:10.21037/jtd.2018.05.68
PMID:29997942
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6006117/
Abstract

BACKGROUND

Pathologic complete response (pCR) is dominant prognostic factor determining favorable outcome in locally advanced non-small cell lung cancer (NSCLC) after induction therapy (IT). There is no non-operative diagnostics that adequately estimates the pCR. Aim of this retrospective study was to assess the correlation between clinical and pathological factors in patients with pCR.

METHODS

Twenty-five patients with pCR after curative lung resection following IT were assessed using univariate and multivariate Cox regression and descriptive analysis. The survival rate was estimated by Kaplan-Meier method.

RESULTS

The IT included chemoradiation with median doses of 50.4 Gy (range, 45-59.4 Gy) combined with platinum-based chemotherapy in 23 patients (92%) and induction platinum-based chemotherapy in 2 patients (8%). Clinical tumor stage before IT was IIIA in 21, IIIB in 4 patients. Mean interval between IT and surgery was 8.1±3.0 weeks. Perioperative morbidity and 30-day mortality was 32% and 4%, respectively. There was no significant correlation of pCR and different clinical and pathological factors. The estimated 5-year long-term survival (LTS) and progressive-free survival (PFS) was 57% and 54%, respectively. The median LTS and PFS was not reached.

CONCLUSIONS

pCR in patients with locally advanced NSCLC following IT is an independent prognostic factor, without correlation with pathological and clinical factors. Non-operative accurate assessment of pCR is currently impossible. Surgical resection enables secure identification of pCR and might improve the patient stratification for additive therapy.

摘要

背景

病理完全缓解(pCR)是决定局部晚期非小细胞肺癌(NSCLC)诱导治疗(IT)后良好预后的主要预后因素。目前尚无充分评估pCR的非手术诊断方法。本回顾性研究的目的是评估pCR患者临床因素与病理因素之间的相关性。

方法

对25例IT后行根治性肺切除且达到pCR的患者进行单因素和多因素Cox回归分析及描述性分析。采用Kaplan-Meier法估计生存率。

结果

IT包括中位剂量为50.4 Gy(范围45 - 59.4 Gy)的放化疗,23例患者(92%)联合铂类化疗,2例患者(8%)接受诱导铂类化疗。IT前临床肿瘤分期为IIIA期21例,IIIB期4例。IT与手术的平均间隔时间为8.1±3.0周。围手术期发病率和30天死亡率分别为32%和4%。pCR与不同临床及病理因素之间无显著相关性。估计5年长期生存率(LTS)和无进展生存率(PFS)分别为57%和54%。未达到中位LTS和PFS。

结论

局部晚期NSCLC患者IT后的pCR是独立的预后因素,与病理和临床因素无关。目前无法通过非手术方法准确评估pCR。手术切除能够可靠地识别pCR,并可能改善辅助治疗的患者分层。